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Abstract
Hepatitis C virus (HCV)-infected patients often use multiple medications to treat infection, 
adverse events related to HCV therapy, or to manage other comorbidities. Drug-drug inter-
actions (DDIs) associated with this polypharmacy are important in HCV pharmacotherapy, 
especially after introduction of direct-acting antivirals (DAAs). Knowledge about pharma-
cokinetics, metabolism, and disposition of drugs used in the treatment of HCV and comor-
bidities is crucial in the interpretation of these data and management of these interactions 
(e.g. dose adjustments, therapeutic drug monitoring, or safe alternatives). Web-based DDIs 
interactive tools like http://www.hep-druginteractions.org represent the most feasible and 
comprehensive way for an assessment of potential DDIs before, during, and after treat-
ment. Additional helpful resources are data from clinical drug interaction studies as well 
as recent real-life data. This chapter is practical overview of DDIs in the treatment of HCV 
with the last update.
Keywords: hepatitis C virus, direct-acting antivirals, drug-drug interactions, cytochrome 
P450, antiviral therapy
1. Introduction
Hepatitis C virus (HCV) is one of the leading causes of liver disease in the world [1, 2]. HCV 
can cause acute and chronic infections. Acute infection is a non-life threatening disease and 
ranges from being asymptomatic to causing a self-limited hepatitis. Acute HCV infection is 
usually asymptomatic and is only very rarely associated with life-threatening disease. About 
15–45% of acutely infected patients spontaneously clear HCV within several months after 
infection, but the remaining 55–85% of patients develop chronic infection [3, 4]. Currently, 
almost 180 million people in the world have chronic HCV infection [2, 3]. The risk of cirrhosis 
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
NonCommercial 4.0 License (https://creativecommons.org/l censes/b -nc/4 0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
of the liver is between 15 and 30% within 20 years for patients with chronic HCV infection, 
and the risk of hepatocellular carcinoma increases (HCC) more than 20-fold within 20 years 
of infection. Approximately, 700,000 persons die each year from HCV-related complications, 
which include cirrhosis, hepatocellular carcinoma (HCC), and liver failure [4].
The goal of therapy is to cure HCV infection in order to prevent the complications of HCV-
related liver and extrahepatic diseases, such as fibrosis, cirrhosis, decompensation of cirrho-
sis, HCC, severe extrahepatic manifestations, and death [4]. The gold standard of therapy for 
the treatment of chronic HCV infection for many years was pegylated interferon (Peg-INF) in 
combination with ribavirin (RBV). Over the past decade, the treatment of hepatitis C has dra-
matically improved. Limited efficacy in patients with HCV and side effects of indirect drugs, 
Peg-INF + RBV spurred the development of new therapeutic approaches. Almost 80 percent 
of patients receiving Peg-INF + RBV combination therapy for chronic HCV infection had side 
effects. The appropriate anticipation and prevention of side effects, proper response when 
they occur, as well as recognition of patients at increased risk for side effects have pivotal 
role in the care of patients with chronic HCV infection. Furthermore, the ability to achieve a 
sustained virologic response (SVR) to therapy depends in part upon the degree of compliance 
with therapy. Reduction of the dose of these agents as well as their discontinuation due to 
side effects could potentially compromise the outcome.
Peg-INF can cause in many cases bone marrow depression with decreased granulocytes, which 
can lead to opportunistic infections and decreased numbers of thrombocytes [5]. Neutropenia 
is one of the most common reasons for dose modification. Flu-like symptoms usually occur 
during the first week of treatment and include chills, headaches, myalgia, and fever. Severe 
fatigue, apathy, and irritability are neuropsychiatric side effects, which are great problem for 
patients and their families. They can even lead to suicide if they are not recognized on time [5]. 
A variety of autoimmune diseases can develop or be exacerbated during peginterferon-con-
taining therapy, including psoriasis, vitiligo, rheumatoid arthritis, lichen planus, sarcoidosis, 
dermatitis herpetiformis, and type 1 diabetes mellitus [5]. Thus, peginterferon should be used 
with caution in patients with known autoimmune disease and is contraindicated in patients 
with known autoimmune hepatitis. The development of thyroid dysfunction is common in 
patients treated with peginterferon. On the other hand, most common side effect of RBV is 
hemolytic anemia. It may be necessary to lower the dose or even discontinue the therapy. In 
those cases, treatment with erythropoietin can reverse ribavirin-associated anemia and permit 
continuation of the RBV therapy [5]. The above-mentioned side effects, decreased adherence to 
therapy, prolonged treatment time as well as increased cost of HCV treatment are all hurdles 
to successful treatment.
2. Direct-acting antivirals (DAAs)
Before 2011, the gold standard of therapy was based on the combination of Peg-IFN and RBV 
that acts by mechanisms not completely known and exhibited low efficacy in most popula-
tions. In the recent years, thanks to basic research on HCV structure and replicative cycle, it 
has been possible to develop DAAs that have dramatically increased the viral clearance rates.
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Specifically, the advent of the combined therapy employing DAAs has dramatically increased 
the viral clearance rate from 40–50% with peginterferon + ribavirin to more than 95% with 
the current therapy [3, 6]. Initially, DAAs for treatments of chronic HCV were more effica-
cious, but had even more side effects at beginning due to combined therapy PEG INF + riba-
virin + DAAs (protease inhibitor) (PI). Some of the side effects of combination Peg INF + RBV+ 
PI inhibitors appeared due to drug-drug interactions. The first generation of NS3/4APIs 
(boceprevir and telaprevir) was approved for clinical use in 2011. Since then, the new stan-
dard in the treatment of chronic HCV infection became triple therapy consisting PEG INF/
RBV and either boceprevir (BOC) or telaprevir (TVP). With the addition of boceprevir or tela-
previr to PEG-IFN/RBV, cure rates for HCV genotype 1 increased to 60–70%. However, new 
protease inhibitors (PI)-containing triple therapy were also accompanied by new problems, 
including more complicated dosing regimens and increased adverse events, which were in 
some cases severe, particularly in patients with advanced liver disease. Furthermore, DDIs 
became additional challenges in HCV therapy. The first DAAs are metabolized by CYP3A4 
and used transporter P-glycoprotein (P-gp) system. As a result, there is potential risk for DDIs 
with other drugs often used in the treatment of HCV patients. By 2013, the second generation 
of DAAs, including sofosbuvir, was introduced in the market.
Direct-acting antivirals target three of the main proteins involved in viral replication: the 
NS3/4A protease, the NS5B polymerase, and the NS5A [7].
2.1. NS3/4A protease inhibitors
NS3/4A protease inhibitors are inhibitors of the NS3/4A serine protease, an enzyme involved 
in post-translational processing and replication of HCV. Protease inhibitors disrupt HCV by 
blocking the NS3 catalytic site or the NS3/NS4A interaction. In addition to its role in viral 
processing, the NS3/NS4A protease blocks TRIF-mediated Toll-like receptor signaling and 
Cardif-mediated retinoic acid–inducible gene 1 (RIG-1) signaling, which result in impaired 
induction of interferons and blocking viral elimination. Thus, inhibition of the NS3/4A prote-
ase could contribute to antiviral activity through two mechanisms [7].
Following the introduction of other potent and better tolerated DAAs, the clinical importance of 
these agents diminished substantially because of their cumbersome administration, substantial 
adverse effects, drug-drug interactions, and low barrier to resistance. The subsequent wave of 
the first generation protease inhibitors (simeprevir, paritaprevir) as well as second generation 
(grazoprevir) offered several benefits over earlier protease inhibitors, including fewer drug-
drug interactions, improved dosing schedules, and less frequent and less severe side effects. In 
addition, the newer protease inhibitors also appear to have increased efficacy against genotype 
1 HCV and other genotypes. Grazoprevir, paritaprevir, and simeprevir are protease inhibitors 
available in the Europe and United States. Asunaprevir is a protease inhibitor used in Japan [7].
2.2. NS5A inhibitors
The NS5A protein plays a role in both viral replication and the assembly of the hepatitis C 
virus (HCV) [7]. However, the precise molecular mechanisms by which NS5A accomplishes 
these functions are unclear. NS5A inhibitors are generally quite potent and effective across all 
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genotypes. However, they have a low barrier to resistance and have variable toxicity profiles 
(Table 1). They have been shown to significantly reduce HCV RNA levels and enhance SVR 
when given in conjunction with peginterferon and ribavirin [18]. They also result in very high 
SVR rates among patients with genotype 1 infection when given in combination with other 
DAAs with or without ribavirin [8].
Available NS5A inhibitors are ledipasvir, ombitasvir, velpatasvir, and elbasvir, each available 
in fixed-dose combinations with other direct-acting antivirals, and daclatasvir. Daclatasvir is 
a NS5A inhibitor that is used mainly in combination with sofosbuvir [7].
2.3. NS5B RNA-dependent RNA polymerase inhibitors
NS5B RNA-dependent RNA polymerase is an enzyme necessary for replication of HCV, 
involved in post-translational processing of HCV and has a catalytic site for nucleoside bind-
ing and at least four other sites at which a non-nucleoside compound can bind and cause 
allosteric alteration. The enzyme’s structure is highly conserved across all HCV genotypes, 
giving agents that inhibit NS5B efficacy against all six genotypes [7]. There are two classes 
of polymerase inhibitors: non-nucleoside analogues (NNPIs) and nucleoside/nucleotide ana-
logues (NPIs). The NNPIs act as allosteric inhibitors, whereas NPIs target the catalytic site of 
NS5B and result in chain termination during RNA replication of the viral genome.
Sofosbuvir was the first NS5B NPIs available in the Europe and United States and can be used 
in various combinations with other antivirals for different indications.
As a class, NNPIs are less potent, more genotype specific (optimized for genotype 1), have a low-
to-moderate barriers to resistance and have variable toxicity profiles [7]. Consequently, this class 
of drug was developed primarily as an adjunct to more potent compounds with higher barriers 
to resistance. Dasabuvir is administered and packaged with ombitasvir-paritaprevir-ritonavir.
Also, “the second generation” PIs, simeprevir, resulted in similar SVR rates when added to 
PEG-IFN/RBV. By 2014, IFN-free regimens had essentially replaced interferon-based therapy. 
Sofosbuvir/ledipasvir and sofosbuvir/simeprevir/RBV resulted in genotype 1 SVR rates of 
92–100%. Combination of ombitasvir, paritaprevir/ritonavir/dasabuvir with/without RBV 
achieved SVR rates as high as 100%. The next step in the clinical development of anti-HCV 
therapy was by 2016 with the availability of pangenotypic ultrarapid (4–8 weeks) single pill 
regimens such as grazoprevir/elbasvir. This review is focused on drug-drug interactions in 
the treatment of HCV infections in past several years.
3. Metabolic pathways of DAAs
Most of the interactions are linked to metabolism of cytochrome P450-3 A4 (CYP3A4) or 
hepatic and/or intestinal transporters such as organic anion-transporting polypeptide (OATP) 
and P-glycoprotein (P-gp) as shown in Table 1 [8]. To a lesser extent, other pathways can be 
involved such as breast cancer resistance protein transporter (BCRP) or multi-drug resistance 
protein 2 (MDRP2).
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Direct antiviral 
agents (DAAs)
Metabolism Transporter Clinical DDI 
extent
Year of 
approval/
withdrawal
Drug in combination 
with
Brand name Comment
Protease 
inhibitors-previrs
Boceprevir AKR, CYP3A4 P-gp
BCRP
High 2011/2014 Not applicable Victrelis No longer available
Telaprevir CYP3A4 P-gp, OATP1B1
OATP2B1
High 2011/2014 Not applicable Incivo No longer available
Simeprevir CYP3A4 P-gp OATP1B1/3
OATP2B1
Moderate 2013 Sofosbuvir Olysio Approved as combination with 
sofosbuvir in 2014
Paritaprevir CYP3A4 P-gp, BCRP
OATP1B1/3
Height 2014
2015
2016
Ombitasvir, dasabuvir, 
ribavirin
Ombitasvir, ribavirin
Ombitasvir, dasabuvir, 
ribavirin
Viekira Pak 
(Technivie)
Viekira XR
Grazoprevir CYP3A4 P-gp, MDRP2, 
OATP1B1
Low 2016 In combination with 
elbasvir
Zepatier
NS5A 
inhibitors-buvirs
Non-nucleoside 
inhibitors
Sofosbuvir Cathepsin A, 
esterases and 
kinases
P-gp and BCRP Low 20132014 Ledipasvir Sovaldi
Harvoni
First treatment without interferon 
or ribavirin
Non-nucleoside 
inhibitors
Dasabuvir High 20142016 Ombitasvir, 
paritaprevir, and 
ribavirin
Viekira 
PakViekira 
XR
NS5A 
inhibitors-asvirs
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Direct antiviral 
agents (DAAs)
Metabolism Transporter Clinical DDI 
extent
Year of 
approval/
withdrawal
Drug in combination 
with
Brand name Comment
Ombitasvir CYP 3A4 P-gp, BCRP High 20142016 Paritaprevir, 
dasabuvir, and 
ribavirin
Viekira Pak
Viekira XR
Ledipasvir Low 2014 Sofosbuvir Harvoni
Daclatasvir CYP3A4 P-gp,BCRP, 
OATP1B1, 
OATP1B3
Low 2015 Daklinza
Elbasvir CYP3A4 P-gp and BCRP Low 2016 Grazoprevir Zepatier To treat GT1–4 including 
compensated cirrhosis, or severe 
kidney disease and on dialysis
Velpatasvir CYP3A4 Inhibits OATP1B1, 
OATP1B3, 
OATP2B1, P-gp, 
BCRP
Low 2016 Sofosbuvir Epclusa First therapy to treat all HCV 
GT 1–6
Adapted according to [8–10].
Table 1. DAAs, metabolism, transporters, potential for DDI, and some basics.
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The good understanding of pharmacokinetic drug profiles is the key to interpret DDIs data. 
DDIs are more likely to occur with 3D regimen, followed by daclatasvir, simeprevir, and ledi-
pasvir, as they are all both substrates and inhibitors of P-gp and/or CYP3A4, than with sofosbu-
vir [8–10]. Their concentrations may be influenced by CYP3A4 and P-gp inducers or inhibitors 
or they can increase concentrations of coadminstered drugs. Low dose or overdosage can be 
expected with potent inducers or inhibitors of drugs with narrow therapeutic range [8–10].
4. Drug-drug interactions with DAAs
Direct antiviral agents (DAAs) improved tolerability and efficacy for HCV-infected patients, 
but drug-drug interactions (DDIs) have the potential to cause harm due to liver dysfunc-
tion and multiple comorbidities. DDIs can be assessed based on information available at 
www.hep-druginteractions.org (http://www.hep-druginteractions.org/) [11]. This website 
was launched in 2010 by members of the Department of Pharmacology at the University of 
Liverpool to offer a resource for healthcare providers, researchers, and patients to be able 
to understand and manage drug-drug interactions. The fact sheets containing information 
on the pharmacokinetics, metabolism, and disposition of each drug are in PDF format. 
Data have been collected from company information, published literature, and are refer-
enced at the end of each sheet. Since pharmacokinetic parameters are dependent on dose 
(and route of administration), data refer to the licensed dose unless otherwise stated.
According to the significance of interactions with DAA, DDIs were assigned to four risk 
categories as follows: classification not possible due to lack of information: category 0; no 
clinically significant interactions expected: category 1; significant interaction possible, may 
require dose adjustment/closer monitoring: category 2; and coadministration either not rec-
ommended or contraindicated: category 3. The regular comedication drugs were sorted into 
different groups according to the organ or system on which they act. When patient use 
more drugs with different risks for a DDI, the highest category was chosen to determine 
the risk for the patient with a respective treatment regimen. Also, the results are presented 
as a “Traffic Light” system (red, amber, and green) to indicate the recommendation. Last 
changes, made recently, include the new category, a yellow: potential interactions likely to 
be of weak intensity where additional action/monitoring or dosage adjustment is unlikely 
to be required [12].
DAAs may share metabolic pathways with drugs, such as antiretroviral drugs, cardiovascular 
drugs, lipid lowering drugs, immunosuppressive drugs, methadone, buprenorphine, herbal 
remedies, and commonly prescribed psychiatric medications, that are commonly used by 
populations with a high prevalence of hepatitis C. In the following text, we review drug inter-
actions with some groups of drugs often used as comedications with DAAs in clinical practice.
4.1. Antiretroviral drugs
Coinfection with HIV and HCV is a serious problem resulting in many complications, includ-
ing faster liver decompensation, cirrhosis, and hepatic carcinoma [4]. One-fourth of patients 
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Class Drug BOC TLP SOF DCV SIM LDV/SOF VEL/SOF 3D EBR/GZR 
N
R
T
Is
 Abacavir          
Emtricitabine          
Lamivudine          
Tenofovir          
N
N
R
T
Is
 
 
Efavirenz          
Etravirine          
Neviparine          
Rilpivirine          
P
Is
 
 
A; A/r; A/C          
D; D/C          
Lopinavir          
E
/I
Is
 
Doluteglavir          
E/C/E/TDF          
E/C/E/TAF          
Maraviroc          
Raltegravir          
NRTIs, nucleoside analog reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PI, 
protease inhibitors; E/I i, entry and integrase inhibitors; A, atazanavir; A/r, atazanavir/ritonavir; A/C, atazanavir/cobicistat; 
D, darunavir; D/C, darunavir/cobicistat; E/C/E/TDF, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; 
E/C/E/TA, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; LDV/SOF-ledipasvir + sofosbuvir; VEL/SOF-
velpatasvir + sofosbuvir; 3D, ritonavir boosted paritaprevir + ombitasvir + dasabuvir; EBR/GZR, elbasvir + grazoprevir.
Green-no clinically significant interaction expected. Red-contraindication. Amber-potential interaction; dose adjustment, 
altered timing of administration, or require monitoring.
Adapted according to www.hep-druginteractions.org (University of Liverpool).
Table 2. Drug-drug interactions between HCV DAAs and HIV antiretrovirals.
infected with HIV concomitantly have HCV infection [13]. After introducing highly active 
antiretroviral drugs in therapy, liver complications became the leading cause of morbidity 
and mortality in HIV-HCV coinfected population.
Optimal treatment is necessary to avoid such complications. It is very important to address 
drug-drug interactions between these two regimens to avoid adverse effects and a decrease 
in efficacy, thereby increasing adherence to therapy. Some of DAAs (e.g. simeprevir, follow-
ing fixed combination VEL/SOF, 3D, and EBR/GZR) are not recommended for use with many 
HIV antiretroviral (ARV) drugs as well as efavirenz, etravirine, and nevirapine. Sofosbuvir 
and fixed combination LDV/SOF can be safely administered with many antiretroviral drugs 
used to treat coinfections (HCV and HIV) (Table 2).
The combination ledipasvir/sofosbuvir can be used with all ARVs. However, these combi-
nations should be used with frequent renal monitoring when a pharmacokinetic enhancer 
(ritonavir or cobicistat) is present in an ARV regimen due to an increase in tenofovir con-
centrations. Also, tenofovir concentration is increased in efavirenz-containing regimens and 
renal monitoring is necessary.
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4.2. Immunosuppressive agents (including steroids)
The most important drug interactions of DAAs are those with immunosuppressants, such as 
tacrolimus and cyclosporine [14]. These immunosuppressants are substrates of both CYP3A 
and P-gp, and inhibitory effects of boceprevir and telaprevir on CYP3A and P-gp increased 
plasma concentrations of the immunosuppressants. In particular, the interaction between 
tacrolimus and telaprevir had a magnitude that was unprecedented in clinical pharmacology: 
the AUC of tacrolimus is increased by 70.3-fold, and this combination would be lethal if doses 
were not adjusted [15]. From the start of combined treatment, therapeutic drug monitoring of 
immunosuppressants with dose adjustment can solve this problem (about 50% of observed 
differences in healthy volunteers) [16].
The combined therapy of telaprevir and boceprevir with systemically applied corticosteroids, 
such as methylprednisolone and prednisone, is not recommended due to risk of Cushing syn-
drome. These corticosteroids are CYP3A4 substrates and higher steroid levels can be expected. 
Similar situation is for locally applied corticosteroids by inhalation or intranasally such as flutica-
sone and budesonide. According to available data, beclomethasone can be used safely in patients 
on strong CYP3A inhibitors [16] and represents a corticosteroid of choice in patients with HCV 
therapy.
Also, sofosbuvir as DAAs in combination with daclatasvir or velpatasvir can be used when 
co-treatment is necessary with immunosuppressants or corticosteroids (Table 3).
Class Drug BOC TLP SOF DCV SIM LDV/SOF VEL/SOF 3D EBR/GZR 
Im
m
u
n
o
su
p
re
ss
iv
e
s Azathioprine          
Cyclosporine          
Everolimus          
Mycophenolate          
Sirolimus          
Tacrolimus          
C
o
r
co
st
e
ro
id
s.
 
Beclomethason          
Dexamethasone          
Momethasone          
Prednisone          
Methylprednisolone          
Hydrocortsone top.          
LDV/SOF, ledipasvir + sofosbuvir; VEL/SOF, velpatasvir + sofosbuvir; 3D, ritonavir boosted paritaprevir + ombitasvir + 
dasabuvir; EBR/GZR, elbasvir + grazoprevir; top, topical.
Green-no clinically significant interaction expected. Red-contraindication. Amber-potential interaction; dose adjustment, 
altered timing of administration, or require monitoring.
Adapted according to www.hep-drugineractions.org (University of Liverpool).
Table 3. DDIs between DAAs and immunosuppressive agents (including corticosteroids).
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4.3. Psychoactive agents
The prevalence of mental disorders remains high among untreated HCV-infected patients 
[17, 18]. In one retrospective study, the authors reported that 86% of HCV-infected patients 
had at least one psychiatric-, drug-, or alcohol use-related disorder recorded in their patient 
data. The most common conditions were depressive disorders (50%) and psychosis (50%), 
followed by anxiety disorders (41%), post-traumatic stress disorders (34%), and bipolar 
disorders (16%) [19]. The majority of DAAs are extensively metabolized by liver enzymes 
and have the ability to influence cytochrome P450 (CYP) enzymes, as well as majority of 
psychoactive medications. However, remarkably little information is available on DDIs 
between psychoactive medications and DAAs. Smolders et al. made overview of the interac-
tion mechanisms between DAAs and psychoactive agents [20]. In addition, they described 
evidenced-based interactions between DAAs and psychoactive drugs and identified safe 
options for the simultaneous treatment of mental illnesses and chronic HCV infection [20]. 
Boceprevir, telaprevir, and the combination paritaprevir/ritonavir plus ombitasvir with das-
abuvir were most likely to cause drug interactions by inhibition of cytochrome P450 (CYP) 
3A4 [11]. Escitalopram and citalopram have been studied in combination with most direct-
acting antivirals (DAAs) and either of these drugs can be safely combined with hepatitis 
Drug Drug BOC TLP SOF DCV SIM LDV/SOF VEL/SOF 3D EBR/GZR 
A
n

-d
e
p
re
ss
a
n
ts
 
Amitriptyline          
Citalopram          
Duloxene          
Escitalopram          
Fluoxene          
Paroxene          
Sertraline          
Trazodone          
Trimipramine          
Venlafaxine          
A
n

p
sy
ch
o

cs
 
Amisulpiride          
Ariprazole          
Chlorpromazine          
Clozapine          
Flupenxol          
Haloperidol          
Olanzapine          
Paliperidone          
Queapine          
Risperidone          
Zuclopenxol          
LDV/SOF, ledipasvir + sofosbuvir; VEL/SOF, velpatasvir + sofosbuvir; 3D, ritonavir boosted paritaprevir + ombitasvir + 
dasabuvir; EBR/GZR, elbasvir + grazoprevir.
Green-no clinically significant interaction expected. Red-contraindication. Amber-potential interaction; dose adjustment, 
altered timing of administration, or require monitoring.
Adapted according to www.hep-druginteractions.org (University of Liverpool).
Table 4. DDI between DAAs and psychoactive agents.
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C virus (HCV) treatment besides boceprevir and telaprevir [11, 20]. No formal interaction 
studies between psychoactive agents and sofosbuvir or ledipasvir have been performed in 
humans. However, these DAAs are generally neither victims nor perpetrators of drug inter-
actions and can, therefore, be safely used in combination with psychoactive drugs (Table 4) 
[11, 20].
Class Drugs BOC TLP SOF DCV SIM LDV/SOF VEL/SOF 3D EBR/GZR 
A
n

a
rh
y
tm
y
ic
s Amiodarone          
Digoxine          
Flecainide          
Vernakalant          
A
n

p
la
te
le
ts
 
a
n
d
  
a
n

ca
o
g
u
la
n
ts
Clopidogrel          
Dabigatran          
Ticagretor          
Warfarin          
B
e
ta
 b
lo
ck
e
rs
 
 
Atenolol          
Bisoprolol          
Carvedilol          
Propranolol          
C
a
lc
iu
m
 
ch
a
n
n
e
l 
b
lo
ck
e
rs
 
Amlodipine          
Dilazem          
Nifedipine          
H
Y
p
e
rt
e
n
si
o
n
  
a
n
d
 h
e
a
rt
 
fa
il
u
re
 a
g
e
n
ts
 Aliskrein          
Candesartan          
Doxazosin          
Enalapril          
S
ta

n
s 
Atorvastan          
Fluvastan          
Pivastan          
Pravastan          
Rosuvastan          
Simvastan          
LDV/SOF, ledipasvir + sofosbuvir; VEL/SOF, velpatasvir + sofosbuvir; 3D, ritonavir boosted paritaprevir + ombitasvir + 
dasabuvir; EBR/GZR, elbasvir + grazoprevir.
Green-no clinically significant interaction expected. Red-clinically significant interaction; contra-indication. Amber-
clinically significant interaction; potential interaction-dose adjustment, altered timing of administration, or require 
monitoring.
Adopted according to www.hep-druginteractions.org (University of Liverpool).
Table 5. DDI between DAAs and cardiovascular drugs.
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4.4. Cardiovascular drugs
Calcium channel blockers are CYP3A and partly P-gp substrates and, thus, increased exposure 
can be expected with CYP3A inhibitors. In that, sofosbuvir is drug of choice due to its metabo-
lism by other metabolic pathways. Antiarrhythmics have a narrow therapeutic window, and 
some are CYP substrates (e.g. amiodarone). Amiodarone is contraindicated with many DAAs, 
except simeprevir and combination elbasvir/grazoprevir (Table 5). Digoxin has been tested 
with telaprevir as prototype of P-gp substrate. Levels of digoxin were increased by 85% with 
telaprevir, which is a moderate inhibitor [15]). Although, according to hep.interactions no clini-
cally significant interactions between warfarin and DAAs, there is one case report in the avail-
able literature [21].
Many statins are both CYP3A substrates and inhibitors of telaprevir and boceprevir. DAAs 
are expected to increase statin levels and the associated risk of severe toxicity such as rhab-
domyolysis [16]. Atorvastatin levels were elevated almost eight times with telaprevir, and 
this combination is contraindicated. Atorvastatin level were elevated 2.3 times with bocepre-
vir, but this interaction can be manageable by staring with low dose of atorvastatin. In the 
case of pravastatin, levels were marginally increased when combined with boceprevir (1.5-
fold), and it probably caused inhibition of OATP1B1. According to some clinicians, it is 
possible to temporarily stop the statins during relatively short treatment to avoid toxicity 
with DAAs.
4.5. Proton pump inhibitors (PPIs)
Depending on the DAA regimen, one of the most frequent drug classes involved in signif-
icant DDIs (category 2 or 3) is PPIs. Acid-reducing agents reduce the absorption of some 
DAAs (e.g. ledipasvir, velpatasvir) and, therefore, its serum concentrations. An observational 
study called Target has reported an association between the use of acid-reducing agents and 
decreased effectiveness of Harvoni (sofosbuvir-ledipasvir) [22]. In Target, participants who 
used PPIs had a cure rate of 93% vs. a cure rate of 98% in people who did not use PPIs. In that 
case, combination elbasvir/grazoprevir was a better choice (Table 6).
Class Drug BOC TLP DCL SIM SOF LDV/SOF VEL/SOF 3D ELB/GRA 
P
P
Is
 
Esomeprazole          
Lansoprazole          
Omeprazole          
Pantoprazole          
Rabeprazole          
LDV/SOF, ledipasvir + sofosbuvir; VEL/SOF, velpatasvir + sofosbuvir; 3D, ritonavir boosted paritaprevir + ombitasvir + 
 dasabuvir; EBR/GZR, elbasvir + grazoprevir.
Green-no clinically significant interaction expected. Red-contraindication. Amber-potential interaction; dose adjustment, 
altered timing of administration, or require monitoring.
Adopted according to www.hep-druginteractions.org (University of Liverpool).
Table 6. DDI between DAAs and PPIs.
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5. Real-life studies
The first real-life study with boceprevir and telaprevir was published in 2013 [23]. In this 
study, 101 patients were selected for treatment in one center. All changes to comedications 
before and during treatment were documented. Drugs were checked for DDIs with telaprevir 
and boceprevir using DDI website resources and categorized into groups according to traffic 
lights (red, amber, and green). Similar to the general population, HCV patients often suffered 
from various common comorbidities like hypertension, dyslipoproteinemia, or atrial arrhyth-
mia. Furthermore, some comorbidities like diabetes and thyroid disorders may even be over-
represented in the HCV-infected population. There was no clinically significant risk in 62% 
drugs, whereas for 29% drugs, some DDI were suspected. However, dose modifications or 
careful monitoring were sufficient for management. Only 4% of drugs were contraindicated 
for co-administration with DAAs. However, 10% of patients took one of these contraindicated 
drugs. Fourthy nine of patients were suspected to be at risk for experiencing significant DDIs. 
Drug classes most often suspected to be involved in significant DDI were thyroid hormones, 
dihydropyridine derivatives, and herbal/alternative drugs. In 16% of the patients, at least one 
drug of the regular outpatient medication was stopped before DAA treatment. Overall, sus-
pected DDIs were managed by dose adjustments and discontinuation of comedication before 
or during DAAs therapy in 75 and 21% of the patients.
After this study, the other real-life studies were published. They include monoinfected HCV 
group, coinfected HIV/HCV group, and elderly patients with different severity of liver disease 
[24–27]. In all studies, the potential for DDIs between DAAs and comedications was assessed 
using www.hep-druginteractions.org. In the real-word large cohort study, Ze Siederdissen 
et al. assessed significance of DDIs between DAAs therapies and regular medications. During 
the period between 2011 and 2014, 261 patients with HCV were selected for DAAs therapy 
and asked for their regular outpatient therapy. Twenty percent of patients did not use any 
comedications. The median number was two drugs (range 0–15). The highest risk to cause 
significant DDIs had ombitasvir/paritaprevir/ritonavir ± dasabuvir (66.3%), in contrast with 
sofosbuvir/ribavirin that possessed lowest risk (9.6%). Significant DDIs for sofosbuvir/ledi-
pasvir would be expected in 40.2%, for sofosbuvir/daclatasvir in 36.8%, and for sofosbuvir/
simeprevir in 31.4%. The most frequently used comedication drugs that possess risk of DDIs 
were proton pump inhibitors, thyroid hormones, and dihydropyridine derivatives.
Gussio et al. assessed the clinical significance of DDI with DAA in a real-world polycentric 
retrospective study involving five clinical unit of infectious diseases in south of Italy and 
Sardinia treating HCV monoinfected and coinfected subjects selected for DAA therapy [25]. 
Two hundred and fifteen (215) subjects were enrolled in the study. Of the total, 139 were 
HCV monoinfected and 76 HIV coinfected. One hundred and seventy patients (170 or 75%) 
were males; median age was 55 years with stage of fibrosis F4 in 70% of patients. At least 
one comorbidity was found in 146 patients (68 and 67%, respectively, within mono and HIV 
coinfected). HCV monoinfected and HIV coinfected subjects had medians of 2 and 1 comor-
bidities, respectively. Regarding DAA drug-drug interactions, sofosbuvir/daclatasvir had the 
lowest risk to cause a potentially significant DDI (20%). In contrast, for ombitasvir/parita-
previr/ritonavir ± dasabuvir, there was potentially significant DDIs (49.8%). Significant DDIs 
Direct-Acting Antivirals (DAAs): Drug-Drug Interactions (DDIs) in the Treatment of Hepatitis C Virus (HCV)
http://dx.doi.org/10.5772/intechopen.70788
87
for sofosbuvir/simeprevir were expected in 30.8%, for sofosbuvir/ribavirin in 28.2%, and for 
sofosbuvir/ledipasvir in 39.8%. Proton pump inhibitors, diuretics, and some antihypertensive 
drugs were frequently used and presented a risk of interacting with the antiviral regimen. 
Antiretroviral regimens also showed a high risk of potential interactions, although 16% of 
patients had preventively modified this treatment.
Kondili et al. assessed the potential DDIs of DAAs in HCV-infected outpatients. They 
evaluated 449 patients in 25 clinical centers in one Italian prospective multicenter study 
[26]. Patients started a DAA regimen and received comedications between March 2015 and 
March 2016. From total number of patients, 86 had mild liver disease and 363 had moderate-
to-severe disease. The utilization of more than three drugs was more frequent in the patients 
with moderate-to-severe disease, whereas the use of single drug as a comedication was 
more frequent in patients with mild liver disease. About 30% (26/86) of patients with mild 
liver disease used at least one drug with a potential DDI, whereas 44% (161/363) of patients 
with moderate-to-severe liver disease were at risk for one or more DDI. Twenty percent of 
drugs (27/142) used as comedications in 86 patients with mild disease may require dose 
adjustment or closer monitoring, whereas none was contraindicated. Twenty five per-
cent (82/322) of comedicated drugs in 363 patients with moderate-to-severe liver disease 
were classified as potential DDOs that required monitoring and dose adjustments and 3% 
(10/322) were contraindicated in severe liver disease. Patients with moderate-to-severe liver 
disease require much more attention due to potential DDI during DAA therapy according 
to the data from this study.
Direct antiviral therapies for chronic hepatitis C virus (HCV) infection have expanded treat-
ment options for neglected patient populations, including elderly patients who are ineligible/
intolerant to receive interferon (IFN)-based therapy. Vermehren et al. followed 541 patients 
treated with different combinations of direct antiviral agents (DAAs: ledipasvir/sofosbuvir 
±ribavirin; daclatasvir/sofosbuvir ±ribavirin; paritaprevir/ombitasvir ±dasabuvir ±ribavirin 
or simeprevir/sofosbuvir ±ribavirin or sofosbuvir/ribavirin in genotype) [27].
SVR rates were 91 and 98% in patients aged <65 years and ≥65 years, respectively. Elderly patients 
took significantly more concomitant drugs (79% vs. 51%). Patients over the age of 65 years with 
cirrhosis took the highest number of concomitant medications (three per patient-median; range, 
0–10).
The number of patients who experienced treatment-associated adverse events was simi-
lar between the two age groups (63% vs. 65%). However, proportion of predicted clini-
cally significant DDIs was significantly higher in elderly patients (54% vs. 28%). Elderly 
patients are at increased risk for significant DDIs when treated with DAAs for chronic 
HCV infection.
6. Conclusions
Based on these findings, a careful assessment of the regular outpatient medication (all drugs, 
including herbal products/alternative medicines and even illegal drugs e.g. HIV patients/
intravenous users) and subsequent evaluation of potential DDIs with DAAs are absolutely 
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crucial to ensure drug safety in all treated patients. Web-based DDI tools like www.hep-
druginteractions.org represent the best way for an assessment of potential DDIs. However, 
although this web resource includes a huge number of drugs and regular update, some of 
the drugs are not probably covered.
Also, it is impossible to foresee each combination of drug used in the treatment, and data from 
real life are also useful source of information. Some DDIs may occur unexpectedly despite a 
careful evaluation before starting treatment, as demonstrated by the EMA and FDA warning 
against the concomitant use of amiodarone- and sofosbuvir-containing DAA therapy due to 
the occurrence of potentially life-threatening bradycardia.
In summary, thousands of patients are being treated with DAAs and a significant number of 
patients are at risk for DDIs. Although the use of strictly contraindicated comedications seems to 
be rare, a careful assessment of regular medications and a comprehensive evaluation of poten-
tial DDIs with each DAA used for therapy are essential to prevent adverse effects or unneces-
sary risks of treatment failure.
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